1,198.30
+2.84%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Anupam Rasayan India
Its shares trade on NSE under the ticker ANURAS.NS. It has been listed since 24 March 2021. In the fiscal year to 31 March 2026, it reported revenue of ₹23.65bn and net income of ₹1.70bn. At that date it held total assets of ₹80.13bn and shareholders' equity of ₹33.34bn.
Anupam Rasayan India Ltd. manufactures pharmaceutical and specialty chemical products. The company is headquartered in Surat, Gujarat. The company went IPO on 2021-03-24. The Company’s segments include Life Science Related Specialty Chemicals and Other Specialty Chemicals. The company manufactures a variety of life science related specialty chemicals comprising products related to agrochemicals, personal care, and pharmaceuticals. The firm manufactures agro intermediates and agro active ingredients for the agrochemicals industry, which are used in the manufacture of, amongst others, insecticides, fungicides, and herbicides. For the personal care industry, it provides, amongst others, anti-bacterial and ultraviolet protection intermediates, and ingredients. In the pharmaceutical segment, the Company focuses on developing intermediates and key starting materials for active pharmaceutical ingredients. The Company’s other specialty chemicals are used in diverse end-user segments, comprising specialty pigments, specialty dyes and polymer additives.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Materials
- Industry
- Chemicals
- Listed since
- 24 Mar 2021
- Employees
- 1,532
- Website
- anupamrasayan.com ↗
Leadership
Pay as last reported
- Dr. Kiran PatelNon-Executive Chairman of the Board
- Mr. Gopal AgarwalChief Executive Officer₹29.2m
- Mrs. Mona DesaiVice Chairman of the Board and Whole-Time Director, since 2003₹37.5m
- Mr. Amit KhuranaChief Financial Officer₹13.1m
- Mr. Ashish GuptaCompany Secretary and Compliance Officer
- Mr. Anand DesaiManaging Director, Executive Director, since 2003₹37.5m
- Dr. Anuj ThakarWhole-time Director₹11.7m
- Mr. Vikash ChanderSenior Business Manager
- Mr. Ravi DesaiSales Head, since 2024₹13.1m
- Dr. Nileshkumar NaikTechnical Head - Operations₹21.4m
- Mr. Vishal ThakkarDeputy Chief Financial Officer₹10.2m
- Mr. Anand ChatorikarIndependent Director₹300,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 56
- Environment
- 52
- Social
- 90
- Governance
- 28
- Direct emissions (scope 1)
- 87,452 t
- Energy emissions (scope 2)
- 29,602 t
- Value chain emissions (scope 3)
- 253,592 t
- Women in the workforce
- 2.90084%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Anupam Rasayan India Ltd manufactures pharmaceutical and specialty chemical products in Surat, Gujarat.
- The company employs 1,532 full-time employees and operates in Life Science Related Specialty Chemicals.
- Anupam Rasayan India Ltd focuses on developing intermediates for active pharmaceutical ingredients in the pharmaceutical segment.
Weaknesses
- The company's business is limited to specialty chemicals and does not cover other material sectors.
- Anupam Rasayan India Ltd has no presence in international markets beyond India.
- The company's IPO was on 24 March 2021, indicating a relatively new market entry.
Opportunities
- Anupam Rasayan India Ltd can expand its product range in agrochemicals for insecticides and fungicides.
- The company can leverage its expertise in personal care intermediates for ultraviolet protection.
- Growth opportunities exist in the pharmaceutical segment for key starting materials.
Threats
- The company faces competition from established players in the Indian Chemicals sector.
- Anupam Rasayan India Ltd's reliance on the Indian market exposes it to domestic economic fluctuations.
- The company's focus on specialty chemicals may limit its ability to adapt to changing industry trends.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.